Navigation Links
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Date:12/6/2010

EAST HANOVER, N.J., Dec. 6, 2010 /PRNewswire/ -- The Novartis Pharmaceutical Corporation ("Novartis") oral investigational drug LBH589 (panobinostat) demonstrated substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients who had relapsed or had become refractory after an autologous stem cell transplant, according to new data from a Phase II clinical trial presented today(1).

In this pivotal single-arm study, one of the largest ever conducted in this patient population, 82% (n=106) of patients, most in their fifth line of therapy or beyond, achieved disease control (defined as stable disease or better) and 74% (n=96) achieved tumor reduction at a median follow-up of 9.6 months, demonstrating the sustained anticancer activity of LBH589. Partial and complete responses to treatment, the primary endpoint, were observed in 27% of patients (n=35), with a median duration of response of 6.9 months and a median progression-free survival measured at 10.5 months among those 35 patients(1).

These data were presented today at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Florida. Worldwide regulatory filings are planned based on the study results.

Currently, up to 35% of patients with Hodgkin lymphoma relapse or become refractory after initial treatment, which typically involves at least two regimens of combination chemotherapy along with high-dose chemotherapy and stem cell transplant(2). Most patients enrolled in this study had received nearly all of the chemotherapy drugs known to be active in this disease, and 79% had failed an additional round of chemotherapy after a stem cell transplant. In addition, 10% of patients had also received prior allogeneic stem cell transplantations (stem cells from another person) in addition to an autologous transplant (stem cells from the patient). Palliative care is currently the only option remaining for these patients(3,4). '/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Breckenridge Pharmaceutical, Inc. announced ... with MSN Laboratories Pvt. Ltd. ( Hyderabad, India ... commercialize several new ANDAs.  Under the terms of the ... exclusively to Breckenridge for the U.S. market, and Breckenridge ... Breckenridge and MSN have agreed to develop an oral ...
(Date:12/19/2014)... N.C. , Dec. 19, 2014 ... optimize a product,s web presence to reflect the ... websites, in particular, must meet the needs of ... and culture. According to recent ... than half of the participating companies averaged more ...
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. (OTCQB: ... Corp.) is pleased to provide this review of the ... in 2015. "Over this past year, we ... I am extremely proud to say that Monarch America ... than it has ever been," stated Eric Hagen ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
(Date:12/19/2014)... Energy Textiles is excited to announce ... the world’s leading responsive textile, can now be ... are a number of benefits to wearing Celliant, ... balanced body temperature; which can lead to enhanced ... athletic performance; and overall wellness. In addition, the ...
(Date:12/19/2014)... These vanadium reserves are mostly found ... 151,000 tons of vanadium were produced globally in 2013, ... increased at 6.7% AAGR during the period from 2001 ... being the largest consumer, accounted for more than 90% ... alloy and the chemical industry. , View Full Report ...
(Date:12/19/2014)... (HealthDay News) -- The intestinal bacteria that cause inflammatory ... may be inherited, researchers report. The findings, published ... help in efforts to prevent the disease and treat ... study authors added. "The intestinal bacteria, or ,gut ... have a big impact on your health for the ...
(Date:12/19/2014)... News) -- The cost of cancer treatment can cause ... finds. Researchers examined data from 1,000 people in ... or lung cancer. Of those patients, almost 900 had ... 100 had advanced cancer. Nearly half of the ... bills, which was linked with a poorer health-related quality ...
(Date:12/19/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief financial officer ... Park, Colo. The top executive search firm in the ... than 900 healthcare executives into organizations. , Estes ... access hospital and level IV trauma center, with a ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3
... meet increasing demand for,pharmaceutical packaging in China, ... HON ) announced,today that it has signed a ... Ltd., to provide the Chinese company with,Honeywell,s Aclar(R) ... also provide technical services and training to Haishun,as ...
... 6 CJPS Enterprises, LLC (, http://www.CJPS-Enterprises.com ... resources,to help companies that depend on the automotive ... "Although both industries seem similar in what they ... companies trying to embark,on this diversification initiative have ...
... an independent factor in cancer survival rates and should not ... a study in the November issue of IJCP , ... team of hospital and University-based researchers from Barcelona, Spain, carried ... with cancer. , "We found that there were a ...
... in German . , Opting for ... warning signs of lymphedema: that,s how women with breast ... German Institute for Quality and Efficiency in Health Care ... themselves from this common and distressing adverse effect of ...
... Conference on Cell Therapy for Cardiovascular Disease (IC3D) ... evolving field of cell-based therapies for treating cardiovascular ... "Cellular and Molecular Building Blocks: Strategies for Cardiovascular ... will convene to present basic, core discussions on ...
... 6 Let,s face it: Because of the,economy, typical ... are,becoming luxuries. Today,s budget trimmers who regularly attend a ... make a small,investment in a home yoga practice and ... Balanced Living magazine,s November,issue, now on newsstands, features "The ...
Cached Medicine News:Health News:Honeywell Signs Supply Agreement with Chinese Company for Aclar(R) Film 2Health News:Honeywell Signs Supply Agreement with Chinese Company for Aclar(R) Film 3Health News:CJPS Enterprises to Increase Focus on Automotive Diversification 2Health News:Age is not a key factor in cancer survival, but clinical trials exclude older patients 2Health News:Age is not a key factor in cancer survival, but clinical trials exclude older patients 3Health News:How women can improve their quality of life after breast cancer treatment 2Health News:5th Annual Global Conference on Stem Cell Therapy to be held Jan. 13-16, 2009 in NYC 2Health News:In These Stressful, Budget-Busting Times, It's Wise to Invest in a Home Yoga Practice, Says Natural Solutions Magazine 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: